新版WHO 2016脑肿瘤分类——神经外科医生需要了解什么
该综述回顾WHO 2016脑肿瘤分类及相关文献,介绍将分子特征纳入中枢神经系统肿瘤分类时采用的分层诊断概念。胶质瘤等因所需检测已普及而主要以分子特征定义,室管膜瘤的分子分组虽优于形态学判读,但因所需检测仅在少数机构建立而未纳入WHO 2016分类。
要点
- WHO 2016分类引入分层诊断概念,最高诊断级别为整合诊断,需部分纳入分子特征,较低级别仍允许纯形态学诊断。
- 少突胶质瘤现主要按分子特征定义,因所需检测已普遍建立;室管膜瘤分子分组因所需检测仅在少数机构建立而未纳入WHO 2016分类。
- 针对突变蛋白的分子抗体应可在几乎所有神经病理实验室获得,而不同高通量检测仅在少数第一世界神经病理机构可及。
核心结论
- 神经病理学家在从WHO 2007版向WHO 2016版脑肿瘤分类过渡的阶段面临各种挑战,临床神经肿瘤学家则面对许多新诊断,这些新诊断可带来对疾病更清晰的理解,并可能为其提供更有效的治疗机会。
- 新WHO 2016分类据推测是自1979年首版WHO分类以来修改数量最多的一版,迫使神经肿瘤学领域所有专业人员深入理解新概念。
研究设计与样本
- 综述:回顾WHO 2016脑肿瘤分类,并检索与回顾2007年至今与脑肿瘤分类相关的文献。
主要发现
- 将分子特征纳入中枢神经系统肿瘤分类的想法使新WHO 2016分类的作者遇到不可避免的概念问题,尤其涉及形态学与分子改变的关联。
- 作为解决方案,作者在脑肿瘤分类中引入「分层诊断」概念:较低诊断级别仍允许纯形态学诊断,最高诊断级别为整合诊断,需部分纳入分子特征。
- 少突胶质瘤现主要按分子特征定义,因所需检测已普遍建立。
- 室管膜瘤的分子分组被发现明显优于基于形态学的肿瘤判读,但因所需检测目前仅在少数机构建立而被拒绝纳入WHO 2016分类。
- 针对突变蛋白的分子抗体应可在几乎所有神经病理实验室获得,而不同高通量检测仅在少数第一世界神经病理机构可及。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The understanding of molecular alterations of tumors has severely changed the concept of classification in all fields of pathology. The availability of high-throughput technologies such as next-generation sequencing allows for a much more precise definition of tumor entities. Also in the field of brain tumors a dramatic increase of knowledge has occurred over the last years partially calling into question the purely morphologically based concepts that were used as exclusive defining criteria in the WHO 2007 classification. METHODS: Review of the WHO 2016 classification of brain tumors as well as a search and review of publications in the literature relevant for brain tumor classification from 2007 up to now. RESULTS: The idea of incorporating the molecular features in classifying tumors of the central nervous system led the authors of the new WHO 2016 classification to encounter inevitable conceptual problems, particularly with respect to linking morphology to molecular alterations. As a solution they introduced the concept of a "layered diagnosis" to the classification of brain tumors that still allows at a lower level a purely morphologically based diagnosis while partially forcing the incorporation of molecular characteristics for an "integrated diagnosis" at the highest diagnostic level. In this context the broad availability of molecular assays was debated. On the one hand molecular antibodies specifically targeting mutated proteins should be available in nearly all neuropathological laboratories. On the other hand, different high-throughput assays are accessible only in few first-world neuropathological institutions. As examples oligodendrogliomas are now primarily defined by molecular characteristics since the required assays are generally established, whereas molecular grouping of ependymomas, found to clearly outperform morphologically based tumor interpretation, was rejected from inclusion in the WHO 2016 classification because the required assays are currently only established in a small number of institutions. CONCLUSION: In summary, while neuropathologists have now encountered various challenges in the transitional phase from the previous WHO 2007 version to the new WHO 2016 classification of brain tumors, clinical neurooncologists now face many new diagnoses allowing a clearly improved understanding that could offer them more effective therapeutic opportunities in neurooncological treatment. The new WHO 2016 classification presumably presents the highest number of modifications since the initial WHO classification of 1979 and thereby forces all professionals in the field of neurooncology to intensively understand the new concepts. This review article aims to present the basic concepts of the new WHO 2016 brain tumor classification for neurosurgeons with a focus on neurooncology.
引用
- Banan R, Hartmann C. The new WHO 2016 classification of brain tumors-what neurosurgeons need to know. Acta Neurochir (Wien). 2017. PMID: 28093610. doi:10.1007/s00701-016-3062-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。